Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in BANKFINANCIAL CORP's common stock.

BlackRock, Inc. has filed a Schedule 13G, reporting a 6.8% beneficial ownership stake in BigBear.ai Holdings, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an updated Schedule 13G, revealing a 12.6% beneficial ownership in BlackLine, Inc.'s common stock, held for passive investment purposes.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.5% of Kestrel Group Ltd's Common Stock as of June 30, 2025.

BlackRock, Inc. has reported a 5.9% beneficial ownership stake in Restaurant Brands International Inc., holding over 19.2 million common shares as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.2% of Amrize Ltd's common stock as of June 30, 2025.

BlackRock, Inc. has reported a 5.6% beneficial ownership stake in ATOMERA INC, holding 1,720,244 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 7.1% beneficial ownership stake in TrueBlue Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 1.8% beneficial ownership stake in TScan Therapeutics, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.0% in Virtra Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.2% passive beneficial ownership stake in Zentalis Pharmaceuticals Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.8% in Zymeworks Inc.'s common stock.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a passive beneficial ownership of 3.3% of Aurora Innovation Inc.'s common stock as of June 30, 2025.

BlackRock, Inc. files Schedule 13G, reporting beneficial ownership of 7.8% of Bloom Energy Corporation's Class A stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive beneficial ownership of 4.98% of CBL AND ASSOCIATES PROPERTIES INC common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 8.3% of CVS Health Corporation's common stock as of June 30, 2025.

BlackRock, Inc. has filed an Amendment No. 11 to its Schedule 13G, disclosing a 6.5% beneficial ownership stake in CarMax Inc. common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Arthur J. Gallagher and Co.'s common stock, held for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.8% beneficial ownership stake in SEI Investments Company, totaling 8,492,433 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.2% beneficial ownership stake in Taysha Gene Therapies Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 2.4% passive beneficial ownership stake in Tillys Inc.'s Class A Stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.2% of TRIMAS CORP's common stock as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a passive beneficial ownership of 4.8% in Tucows Inc.'s Class A Stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in CIMPRESS PLC's common stock as of June 30, 2025.

BlackRock, Inc. has reported a 5.9% beneficial ownership stake in Foreign Trade Bank of Latin America Inc., holding over 1.7 million common shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.8% beneficial ownership stake in AGENUS INC's common stock as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in AppLovin Corp's Class A Stock as a passive investor.

BlackRock, Inc. filed an Amendment No. 1 to its Schedule 13G, reporting a 2.0% passive beneficial ownership stake in Artiva Biotherapeutics, Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 6.8% beneficial ownership stake in Beyond Meat, Inc. as of June 30, 2025.

BlackRock, Inc. has reduced its beneficial ownership in C4 Therapeutics, Inc. to 2.5% of the common stock, as disclosed in an amended Schedule 13G filing.